Medical Biology - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/238

Filters

2020 - 2021 3
3
Reset filters

Settings
Statistics
Citations
Author: Strasser, Andreas × Author: Diepstraten, Sarah × Start date: 2020 × End date: 2022 ×

Search Results

Now showing 1 - 3 of 3
  • Item
    No Preview Available
    Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
    Thijssen, R ; Diepstraten, ST ; Moujalled, D ; Chew, E ; Flensburg, C ; Shi, MX ; Dengler, MA ; Litalien, V ; MacRaild, S ; Chen, M ; Anstee, NS ; Reljic, B ; Gabriel, SS ; Djajawi, TM ; Riffkin, CD ; Aubrey, BJ ; Chang, C ; Tai, L ; Xu, Z ; Morley, T ; Pomilio, G ; Bruedigam, C ; Kallies, A ; Stroud, DA ; Bajel, A ; Kluck, RM ; Lane, SW ; Schoumacher, M ; Banquet, S ; Majewski, IJ ; Strasser, A ; Roberts, AW ; Huang, DCS ; Brown, FC ; Kelly, GL ; Wei, AH (AMER SOC HEMATOLOGY, 2021-05-20)
    Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative treatment for patients with various leukemias. TP-53 controls apoptosis upstream of where BCL-2 and its prosurvival relatives, such as MCL-1, act. Therefore, targeting these prosurvival proteins could trigger apoptosis across diverse blood cancers, irrespective of TP53 mutation status. Indeed, targeting BCL-2 has produced clinically relevant responses in blood cancers with aberrant TP-53. However, in our study, TP53-mutated or -deficient myeloid and lymphoid leukemias outcompeted isogenic controls with intact TP-53, unless sufficient concentrations of BH3-mimetics targeting BCL-2 or MCL-1 were applied. Strikingly, tumor cells with TP-53 dysfunction escaped and thrived over time if inhibition of BCL-2 or MCL-1 was sublethal, in part because of an increased threshold for BAX/BAK activation in these cells. Our study revealed the key role of TP-53 in shaping long-term responses to BH3-mimetic drugs and reconciled the disparate pattern of initial clinical response to venetoclax, followed by subsequent treatment failure among patients with TP53-mutant chronic lymphocytic leukemia or acute myeloid leukemia. In contrast to BH3-mimetics targeting just BCL-2 or MCL-1 at doses that are individually sublethal, a combined BH3-mimetic approach targeting both prosurvival proteins enhanced lethality and durably suppressed the leukemia burden, regardless of TP53 mutation status. Our findings highlight the importance of using sufficiently lethal treatment strategies to maximize outcomes of patients with TP53-mutant disease. In addition, our findings caution against use of sublethal BH3-mimetic drug regimens that may enhance the risk of disease progression driven by emergent TP53-mutant clones.
  • Item
    No Preview Available
    BCL-W is dispensable for the sustained survival of select Burkitt lymphoma and diffuse large B-cell lymphoma cell lines
    Diepstraten, ST ; Chang, C ; Tai, L ; Gong, J-N ; Lan, P ; Dowell, AC ; Taylor, GS ; Strasser, A ; Kelly, GL (AMER SOC HEMATOLOGY, 2020-01-28)
    Dysregulated expression of BCL-2 family proteins allows cancer cells to escape apoptosis. To counter this, BH3-mimetic drugs that target and inhibit select BCL-2 prosurvival proteins to induce apoptosis have been developed for cancer therapy. Venetoclax, which targets BCL-2, has been effective as therapy for patients with chronic lymphocytic leukemia, and MCL-1-targeting BH3-mimetic drugs have been extensively evaluated in preclinical studies for a range of blood cancers. Recently, BCL-W, a relatively understudied prosurvival member of the BCL-2 protein family, has been reported to be abnormally upregulated in Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), and Hodgkin lymphoma patient samples. Therefore, to determine if BCL-W would be a promising therapeutic target for B-cell lymphomas, we have examined the role of BCL-W in the sustained growth of human BL- and DLBCL-derived cell lines. We found that CRISPR/CAS9-mediated loss or short hairpin RNA-mediated knockdown of BCL-W expression in selected BL and DLBCL cell lines did not lead to spontaneous apoptosis and had no effect on their sensitivity to a range of BH3-mimetic drugs targeting other BCL-2 prosurvival proteins. Our results suggest that BCL-W is not universally required for the sustained growth and survival of human BL and DLBCL cell lines. Thus, targeting BCL-W in this subset of B-cell lymphomas may not be of broad therapeutic benefit.
  • Item
    No Preview Available
    MCL-1 is essential for survival but dispensable for metabolic fitness of FOXP3+regulatory T cells
    Teh, CE ; Robbins, AK ; Henstridge, DC ; Dewson, G ; Diepstraten, ST ; Kelly, G ; Febbraio, MA ; Gabriel, SS ; O'Reilly, LA ; Strasser, A ; Gray, DHD (SPRINGERNATURE, 2020-12)
    FOXP3+ regulatory T (Treg) cells are essential for maintaining immunological tolerance. Given their importance in immune-related diseases, cancer and obesity, there is increasing interest in targeting the Treg cell compartment therapeutically. New pharmacological inhibitors that specifically target the prosurvival protein MCL-1 may provide this opportunity, as Treg cells are particularly reliant upon this protein. However, there are two distinct isoforms of MCL-1; one located at the outer mitochondrial membrane (OMM) that is required to antagonize apoptosis, and another at the inner mitochondrial membrane (IMM) that is reported to maintain IMM structure and metabolism via ATP production during oxidative phosphorylation. We set out to elucidate the relative importance of these distinct biological functions of MCL-1 in Treg cells to assess whether MCL-1 inhibition might impact upon the metabolism of cells able to resist apoptosis. Conditional deletion of Mcl1 in FOXP3+ Treg cells resulted in a lethal multiorgan autoimmunity due to the depletion of the Treg cell compartment. This striking phenotype was completely rescued by concomitant deletion of the apoptotic effector proteins BAK and BAX, indicating that apoptosis plays a pivotal role in the homeostasis of Treg cells. Notably, MCL-1-deficient Treg cells rescued from apoptosis displayed normal metabolic capacity. Moreover, pharmacological inhibition of MCL-1 in Treg cells resistant to apoptosis did not perturb their metabolic function. We conclude that Treg cells require MCL-1 only to antagonize apoptosis and not for metabolism. Therefore, MCL-1 inhibition could be used to manipulate Treg cell survival for clinical benefit without affecting the metabolic fitness of cells resisting apoptosis.